These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30847645)

  • 1. Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials.
    Hashizume A; Katsuno M; Suzuki K; Banno H; Takeuchi Y; Kawashima M; Suga N; Mano T; Araki A; Hijikata Y; Hirakawa A; Sobue G;
    J Neurol; 2019 May; 266(5):1211-1221. PubMed ID: 30847645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Katsuno M; Banno H; Suzuki K; Takeuchi Y; Kawashima M; Yabe I; Sasaki H; Aoki M; Morita M; Nakano I; Kanai K; Ito S; Ishikawa K; Mizusawa H; Yamamoto T; Tsuji S; Hasegawa K; Shimohata T; Nishizawa M; Miyajima H; Kanda F; Watanabe Y; Nakashima K; Tsujino A; Yamashita T; Uchino M; Fujimoto Y; Tanaka F; Sobue G;
    Lancet Neurol; 2010 Sep; 9(9):875-84. PubMed ID: 20691641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.
    Banno H; Katsuno M; Suzuki K; Takeuchi Y; Kawashima M; Suga N; Takamori M; Ito M; Nakamura T; Matsuo K; Yamada S; Oki Y; Adachi H; Minamiyama M; Waza M; Atsuta N; Watanabe H; Fujimoto Y; Nakashima T; Tanaka F; Doyu M; Sobue G
    Ann Neurol; 2009 Feb; 65(2):140-50. PubMed ID: 19259967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study.
    Hashizume A; Katsuno M; Suzuki K; Hirakawa A; Hijikata Y; Yamada S; Inagaki T; Banno H; Sobue G
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1026-1032. PubMed ID: 28780536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of leuprorelin in bulbar function of spinal and bulbar muscular atrophy patients: observational study for 1 year.
    Kang MG; Gwak DW; Cho HJ; Min YS; Park JS
    J Neurol; 2021 Sep; 268(9):3344-3351. PubMed ID: 33675422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Effects of Androgen Deprivation in a Patient with Spinal and Bulbar Muscular Atrophy - A Case Report with 14 Years of Follow-up.
    Hijikata Y; Hashizume A; Yamada S; Ito D; Banno H; Suzuki K; Sobue G; Katsuno M
    Intern Med; 2019 Aug; 58(15):2231-2234. PubMed ID: 30996158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Disease-modifying therapy for spinal and bulbar muscular atrophy (SBMA)].
    Suzuki K; Banno H; Katsuno M; Adachi H; Tanaka F; Sobue G
    Brain Nerve; 2012 Mar; 64(3):237-44. PubMed ID: 22402717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).
    Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
    Cell Tissue Res; 2012 Jul; 349(1):313-20. PubMed ID: 22476656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS).
    Yamada S; Hashizume A; Hijikata Y; Inagaki T; Ito D; Kinoshita F; Nakatochi M; Kobayashi Y; Hirakawa A; Nakamura T; Katsuno M
    BMJ Open; 2018 Sep; 8(9):e023041. PubMed ID: 30206090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of leuprorelin in spinal and bulbar muscular atrophy: a 3-year observational study.
    Kang MG; Kang M; Cho HJ; Min YS; Park JS
    Neurol Sci; 2024 Aug; 45(8):3853-3859. PubMed ID: 38400888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.
    Fernández-Rhodes LE; Kokkinis AD; White MJ; Watts CA; Auh S; Jeffries NO; Shrader JA; Lehky TJ; Li L; Ryder JE; Levy EW; Solomon BI; Harris-Love MO; La Pean A; Schindler AB; Chen C; Di Prospero NA; Fischbeck KH
    Lancet Neurol; 2011 Feb; 10(2):140-7. PubMed ID: 21216197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.
    Grunseich C; Miller R; Swan T; Glass DJ; El Mouelhi M; Fornaro M; Petricoul O; Vostiar I; Roubenoff R; Meriggioli MN; Kokkinis A; Guber RD; Budron MS; Vissing J; Soraru G; Mozaffar T; Ludolph A; Kissel JT; Fischbeck KH;
    Lancet Neurol; 2018 Dec; 17(12):1043-1052. PubMed ID: 30337273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.
    Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
    Int J Mol Sci; 2009 Mar; 10(3):1000-12. PubMed ID: 19399234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-androgen therapy for spinal and bulbar muscular atrophy (SBMA)].
    Katsuno M; Banno H; Suzuki K; Hashizume A; Adachi H; Tanaka F; Sobue G
    Rinsho Shinkeigaku; 2012; 52(11):1207-9. PubMed ID: 23196565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combined Efficacy of a Two-Year Period of Cybernic Treatment With a Wearable Cyborg Hybrid-Assistive Limb and Leuprorelin Therapy in a Patient With Spinal and Bulbar Muscular Atrophy: A Case Report.
    Nakatsuji H; Ikeda T; Hashizume A; Katsuno M; Sobue G; Nakajima T
    Front Neurol; 2022; 13():905613. PubMed ID: 35812096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial.
    Hijikata Y; Katsuno M; Suzuki K; Hashizume A; Araki A; Yamada S; Inagaki T; Ito D; Hirakawa A; Kinoshita F; Gosho M; Sobue G
    JMIR Res Protoc; 2018 Mar; 7(3):e69. PubMed ID: 29506970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open trial of long-term testosterone suppression in spinal and bulbar muscular atrophy.
    Yamamoto T; Yokota K; Amao R; Maeno T; Haga N; Taguri M; Ohtsu H; Ichikawa Y; Goto J; Tsuji S
    Muscle Nerve; 2013 Jun; 47(6):816-22. PubMed ID: 23512333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Assessment of Swallowing Dysfunction in Patients with Spinal and Bulbar Muscular Atrophy.
    Hashizume A; Banno H; Katsuno M; Hijikata Y; Yamada S; Inagaki T; Suzuki K; Sobue G
    Intern Med; 2017 Dec; 56(23):3159-3165. PubMed ID: 29021456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker.
    Banno H; Adachi H; Katsuno M; Suzuki K; Atsuta N; Watanabe H; Tanaka F; Doyu M; Sobue G
    Ann Neurol; 2006 Mar; 59(3):520-6. PubMed ID: 16358333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.